

Inarzin®

Tablet

Description

Inarzin is a preparation of Cinnarizine which acts as an antihistamine, labyrinthine sedative and a peripheral antivasoconstrictor. Inarzin is a selective calcium antagonist, inhibiting the influx of Ca^{2+} intracellularly. It prevents the Ca^{2+} -dependent contraction of arterial smooth muscle by inhibiting Ca^{2+} influx through smooth muscle calcium channels and thereby, improves vestibular symptoms and prevents peripheral arterial disease.

Indications

Inarzin is indicated for :

- ◆ The control of vestibular symptoms such as vertigo, tinnitus, nausea and vomiting as seen in Meniere's disease
- ◆ The prophylaxis and control of motion sickness
- ◆ The long term treatment of peripheral arterial disease

Dosage and Administration

The recommended dose for treatment of vestibular symptoms in adults and children over 12 years is 30 mg (2 tablets) three times daily. For children from 5 to 12 years half the adult dose is recommended, i.e. 15 mg (1 tablet) three times daily.

For prophylaxis of motion sickness, 30 mg (2 tablets) should be taken 2 hours before travel and then 15 mg (1 tablet) every 8 hours during the journey. Children from 5 to 12 years, should take half the adult dose.

In the management of peripheral arterial disease, the recommended starting dose is 75 mg (5 tablets) three times daily. Maintenance dose is 75 mg (5 tablets) two to three times daily depending upon the therapeutic response. Inarzin should preferably be taken after meals.

Contraindications

- ◆ Known hypersensitivity to Cinnarizine
- ◆ Parkinson's disease
- ◆ Hypotension

Drug Interaction

Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either these drugs or of Cinnarizine. Therefore, it is advisable to avoid these drugs while taking Cinnarizine.

Side Effects

Drowsiness and gastrointestinal disturbances may occur. These are usually transient. In rare cases, headache, dry mouth, etc. may occur.

Use in Special Populations

Neonates : Cinnarizine is not indicated in neonates

Pregnancy :The safety of Cinnarizine in human pregnancy has not been established. Therefore, it is not advisable to administer Cinnarizine in pregnancy.

Lactation :It is not known if Cinnarizine is excreted in human breast milk. Use of Cinnarizine during breast feeding is not advised.

Commercial Pack

Inarzin[®] Tablet : Box containing 100 tablets in 10 x 10's blister strips, each tablet containing Cinnarizine BP 15 mg.